

AUTHOR INDEX

- Albain, K.S., 284
 Almstedt, M., 511
 Altomonte, M., 473, 503
 Arlen, P.M., 549
 Ashton, R.W., 253
- Baggetto, L.G., 583
 Barakat, S., 583
 Barosi, G., 395
 Benimetskaya, L., 563
 Berlin, J.D., 52
 Biddle, V.R., 232
 Blanke, C.D., 69
 Bromer, M.Q., 3
 Browner, L., 145
- Calabrò, L., 503
 Carducci, M.A., 145
 Cervantes, F., 395
 Chagraoui, H., 365
 Cheville, A.L., 219
 Cho, L.C., 293
 Chow, E., 156
 Choy, H., 293
 Chung, D.C., 11
 Cinti, C., 452
 Claus, R., 511
 Cohen, S.D., 237
 Coldwell, D.M., 169
 Collins, T.S., 61
 Coral, S., 473
- Danielli, R., 473
 Dayan, G., 583
 Deeg, H.J., 414
 Degan, M., 503
 de Vos, D., 437
 Di Giacomo, A.M., 473, 503
 DiPaola, R.S., 549
 Dômont, J., 279
 Dowell, J.E., 293
- Feeney, K., 596
 Feigenberg, S., 156
 Fonsatti, E., 503
 Frankel, A.E., 591
 Fratta, E., 473
 French INSERM Network on Myelofibrosis
 With Myeloid Metaplasia, 373
- Garwood, D., 293
 Gattei, V., 503
 Gerson, S., 535
 Gill, S., 24
 Giordano, A., 452
 Goldberg, R.M., 35
 Grem, J.L., 120
 Guis, N.A., 479
- Haller, D.G., 95
 Haluszka, O., 174
 Harrington, K.J., 573
 Herbst, R.S., 315
 Hermiston, T., 537
 Hurwitz, H.I., 61
- Isobe, T., 315
 Issa, J.-P.J., 521
- Jett, J.R., 253
 Jo, W.-S., 11
 Johnson, D.H., 251, 329
- Kairys, J., 596
 Kash, K.M., 211
 Kaufman, H.L., 549
 Kim, P.S., 194
 Kim, D., 537
 Konski, A., 156
 Kunkel, E.J., 211
 Kvasnicka, H.M., 380
- Labialle, S., 583
 Lagman, R., 134
 Lamaj, E., 473
 Laskin, J.J., 251, 329
 Lattime, E.C., 535
 Le Bousse-Kerdiles, M.-C., 373
 Le Chevalier, T., 279
 Levy, M.H., 131, 179, 237
 Lockhart, C., 52
 Lubbert, M., 511
- Macaluso, M., 452
 Mago, R., 211
 Maio, M., 435, 473, 503
 Mani, S., 563
 Martyrre, M.-C., 373
 Massion, P.P., 259
 McLeod, H.L., 113
 Meropol, N.J., 1
 Mesa, R.A., 403
 Michaud, M., 583
 Migliaccio, A.R., 365
 Milch, R.A., 165
 Miller, V.A., 299
 Milton, D.T., 299
 Momparler, R.L., 443
 Montanari, M., 452
 Monti, D.A., 225
 Murgio, A.J., 458
 Mutti, L., 336
- Nguyen, D.M., 488
- Odenike, O., 357, 422
 O'Neil, B.H., 35
 Onn, A., 315
- Paice, J.A., 200
 Pandha, H., 573
 Paoletti, F., 365
 Pass, H.I., 269
 Porta, C., 336
- Reilly, J.T., 359
 Relph, K.L., 573
 Ribas, A., 556
 Rigal, D., 583
 Rosenfeld, C.S., 465
 Ruan, D.T., 85
- Samuel, T.A., 179
 Sanborn, R., 69
 Sandler, A.B., 251, 329
 Schapira, L., 139
 Schrupp, D.S., 488
 Sewell, P.E., 169
 Sigalotti, L., 473, 503
 Sinicrope, F.A., 24
 Soria, J.-C., 279
 Spangler, A., 293
 Stein, C.A., 563
 Suh, D.Y., 591
 Sun, W., 95
- Tan, B.R., 113
 Tefferi, A., 403, 422
 Tejpar, S., 43
 Tensen, C.P., 479
 Thiele, J., 380
 Thorne, S.H., 537
 Torosian, M.H., 232
 Toyota, M., 521
- van Besien, K., 414
 Van Cutsem, E., 43
 van der Velden, P.A., 479
 van Doorn, R., 479
 Vannucchi, A.M., 365
 Verslype, C., 43
 Vogelzang, N.J., 336
 von Mehren, M., 76
 Von Roenn, J.H., 200
- Walsh, D., 134
 Wardwell Jr., N.R., 259
 Warren, R.S., 85
 Weinberg, D.S., 3
 Wendling, F., 365
 West, H., 284
 Willemze, R., 479
 Willett, C.G., 103
 Wong, L., 591
- Yang, J., 225
 Zhu, A.X., 103

AUTHOR INDEX

- Albain, K.S., 284
 Almstedt, M., 511
 Altomonte, M., 473, 503
 Arlen, P.M., 549
 Ashton, R.W., 253
- Baggetto, L.G., 583
 Barakat, S., 583
 Barosi, G., 395
 Benimetskaya, L., 563
 Berlin, J.D., 52
 Biddle, V.R., 232
 Blanke, C.D., 69
 Bromer, M.Q., 3
 Browner, L., 145
- Calabrò, L., 503
 Carducci, M.A., 145
 Cervantes, F., 395
 Chagraoui, H., 365
 Cheville, A.L., 219
 Cho, L.C., 293
 Chow, E., 156
 Choy, H., 293
 Chung, D.C., 11
 Cinti, C., 452
 Claus, R., 511
 Cohen, S.D., 237
 Coldwell, D.M., 169
 Collins, T.S., 61
 Coral, S., 473
- Danielli, R., 473
 Dayan, G., 583
 Deeg, H.J., 414
 Degan, M., 503
 de Vos, D., 437
 Di Giacomo, A.M., 473, 503
 DiPaola, R.S., 549
 Dômont, J., 279
 Dowell, J.E., 293
- Feeney, K., 596
 Feigenberg, S., 156
 Fonsatti, E., 503
 Frankel, A.E., 591
 Fratta, E., 473
 French INSERM Network on Myelofibrosis
 With Myeloid Metaplasia, 373
- Garwood, D., 293
 Gattei, V., 503
 Gerson, S., 535
 Gill, S., 24
 Giordano, A., 452
 Goldberg, R.M., 35
 Grem, J.L., 120
 Guis, N.A., 479
- Haller, D.G., 95
 Haluszka, O., 174
 Harrington, K.J., 573
 Herbst, R.S., 315
 Hermiston, T., 537
 Hurwitz, H.I., 61
- Isobe, T., 315
 Issa, J.-P.J., 521
- Jett, J.R., 253
 Jo, W.-S., 11
 Johnson, D.H., 251, 329
- Kairys, J., 596
 Kash, K.M., 211
 Kaufman, H.L., 549
 Kim, P.S., 194
 Kim, D., 537
 Konski, A., 156
 Kunkel, E.J., 211
 Kvasnicka, H.M., 380
- Labialle, S., 583
 Lagman, R., 134
 Lamaj, E., 473
 Laskin, J.J., 251, 329
 Lattime, E.C., 535
 Le Bousse-Kerdiles, M.-C., 373
 Le Chevalier, T., 279
 Levy, M.H., 131, 179, 237
 Lockhart, C., 52
 Lubbert, M., 511
- Macaluso, M., 452
 Mago, R., 211
 Maio, M., 435, 473, 503
 Mani, S., 563
 Martyrè, M.-C., 373
 Massion, P.P., 259
 McLeod, H.L., 113
 Meropol, N.J., 1
 Mesa, R.A., 403
 Michaud, M., 583
 Migliaccio, A.R., 365
 Milch, R.A., 165
 Miller, V.A., 299
 Milton, D.T., 299
 Momparler, R.L., 443
 Montanari, M., 452
 Monti, D.A., 225
 Murgio, A.J., 458
 Mutti, L., 336
- Nguyen, D.M., 488
- Odenike, O., 357, 422
 O'Neil, B.H., 35
 Onn, A., 315
- Paice, J.A., 200
 Pandha, H., 573
 Paoletti, F., 365
 Pass, H.I., 269
 Porta, C., 336
- Reilly, J.T., 359
 Relph, K.L., 573
 Ribas, A., 556
 Rigal, D., 583
 Rosenfeld, C.S., 465
 Ruan, D.T., 85
- Samuel, T.A., 179
 Sanborn, R., 69
 Sandler, A.B., 251, 329
 Schapira, L., 139
 Schrupp, D.S., 488
 Sewell, P.E., 169
 Sigalotti, L., 473, 503
 Sinicrope, F.A., 24
 Soria, J.-C., 279
 Spangler, A., 293
 Stein, C.A., 563
 Suh, D.Y., 591
 Sun, W., 95
- Tan, B.R., 113
 Tefferi, A., 403, 422
 Tejpar, S., 43
 Tensen, C.P., 479
 Thiele, J., 380
 Thorne, S.H., 537
 Torosian, M.H., 232
 Toyota, M., 521
- van Besien, K., 414
 Van Cutsem, E., 43
 van der Velden, P.A., 479
 van Doorn, R., 479
 Vannucchi, A.M., 365
 Verslype, C., 43
 Vogelzang, N.J., 336
 von Mehren, M., 76
 Von Roenn, J.H., 200
- Walsh, D., 134
 Wardwell Jr., N.R., 259
 Warren, R.S., 85
 Weinberg, D.S., 3
 Wendling, F., 365
 West, H., 284
 Willemze, R., 479
 Willett, C.G., 103
 Wong, L., 591
- Yang, J., 225
 Zhu, A.X., 103

SUBJECT INDEX

- A beta fiber, 198
A delta fiber, 198
Abdominal radiation, for extramedullary hematopoiesis in myelofibrosis with myeloid metaplasia, 408-410
Aberrant crypt foci, 25
 as potential surrogate biomarker, 30-31
Aberrant DNA methylation, in cancer, 521
 causes of
 accelerating factors, 525-526
 gene expression factor, 526
 seed and spread model, 525
 selective advantage, 526-527
 in cutaneous malignancies
 basal cell carcinoma, 480-481
 lymphoma, 483-484
 melanoma, 481-483
 relationship with exposure to ultraviolet radiation, 484
 squamous cell carcinoma, 480-481
Acetaminophen, 183-184
Acupuncture, 226
Acute myelogenous leukemia, clinical development of decitabine for combination therapy, 469
 monotherapy, 468-469
Adenocarcinoma, lung, uracil tegafur adjuvant chemotherapy, 281
Adenomatous polyps, colorectal cancer risk and, 4-5
Adenoviral vectors, for cancer gene therapy, 573-575
 adverse outcomes, 580
 clinical applications, 576
 gene replacement therapy, 578-579
 immunotherapy and, 576-578
 oncolytic virotherapy, 579-580
 suicide gene therapy, 578
 targeting of
 transcriptional, 575-576
 transductional, 575
Affinitak, in non-small cell lung cancer, 320
Age, effects on chemotherapy of non-small cell lung cancer, 308-310
Algomed pump, 195
Allogeneic hemopoietic stem cell transplantation, for myelofibrosis with myeloid metaplasia, 414-419
ALVAC, 80
American Cancer Society, 216
Amsterdam criteria, for hereditary nonpolyposis colon cancer, 16
Analgesic
 for cancer pain relief, 181-184
 co-analgesic, 188
 dosing of, 183-184
 opioid, sequential trials of, 188
Androgens, for anemia in myelofibrosis with myeloid metaplasia, 423
Anemia, in myelofibrosis with myeloid metaplasia, androgens for, 423
Angiogenesis, 61-62
 in myelofibrosis with myeloid metaplasia, 385-386
 pro, factors for, 62
Angiogenesis inhibitors
 in clinical development, 66
 factors for, 62
 in non-small cell lung cancer, 320-323
Angiogenesis inhibitors (*Continued*)
 trials of, in colorectal cancer, 63
Angiogenic myeloid metaplasia, *see* Myelofibrosis with myeloid metaplasia
Angiozyme, in colorectal cancer, 65, 66
Anorexia, 202-204
 pharmacologic agents for, 201
Antiangiogenic agents, for myelofibrosis with myeloid metaplasia, 424-426
Anticonvulsant, as co-analgesic, 189-190
Anti-EGFR monoclonal antibody therapy
 in malignant pleural mesothelioma, 341-343
 in non-small cell lung cancer, 317-318
Antigen
 processing of, 77
 types of, in colorectal cancer, 78
Anti-idiotypic vaccine, trial of, 79
Antineoplastic activity, of decitabine in animal models, 445-446
Antisense oligonucleotides, for oncogene inactivation
 Bcl-2 inhibition by, 568-569
 cellular internalization, 564-565
 chemically synthesized, properties of, 564
 clinical utility of phosphodiester oligonucleotides, 563-564
 for multidrug resistant cancer, 584-585, 587
 phosphorothioate oligonucleotides
 efficacy of, and RNase H, 566
 general properties, 565
 nonspecific effects, 565-566
 pharmacokinetics, 566-569
 second-generation oligonucleotides, pharmacokinetics, 568
Anti-VEGFR monoclonal antibody therapy, in non-small cell lung cancer, 320
Anxiety, treatment of, 212-214
APC gene, 15
 in colorectal screening, 9
Apoptosis
 activation by decitabine in epigenetic cancer therapy, 466
 and proliferation, in myelofibrosis with myeloid metaplasia, 383-385
Argon plasma coagulation, 175
Aspirin
 chemoprevention trial and, 26
 colorectal cancer and, 25-28
Astler-Coller classification, modified, in colorectal cancer, 96
Atypical capsular melanocytes, 596-597
Autofluorescence bronchoscopy, in non-small cell lung cancer screening, 254
Autologous hemopoietic stem cell transplantation, for myelofibrosis with myeloid metaplasia, 419-420
Avastin, in malignant pleural mesothelioma, 343-344
Avipox, 80
5-Aza-2'-deoxycytidine, *see* Decitabine
5-AZA-CdR, *see* Decitabine
Azacitidine, in epigenetic cancer therapy
 combinations with histone deacetylase inhibitors, 461
 dose-schedule optimization of, 459-460
 for myeloid neoplasms, 511-512
 restoring or enhancing sensitivity to other therapy, 460-461
5-AZA-CR, *see* Azacitidine
5-Azacytidine, *see* Azacitidine
Azanucleosides, low-dose, in epigenetic therapy of myeloid neoplasms, 511-512
Azoxymethane, 53

- Baclofen, 187, 189
- Barium enema, double-contrast, 7-8
- Basal cell carcinoma, aberrant DNA methylation in, 480-481
relationship with exposure to ultraviolet radiation, 484
- BAT-26 gene, in colorectal screening, 9
- BAX gene, 27
- Bcl-2 inhibition, by antisense oligonucleotides, 568-569
- Beta-catenin, 14
- Bethesda criteria, for hereditary nonpolyposis colon cancer, 16
- Bevacizumab, 117
in colorectal cancer, 63-65, 66
in combined modality therapy, for colorectal cancer, 109
in malignant pleural mesothelioma, 343-344
in non-small cell lung cancer, 321
- Bexarotene, in non-small cell lung cancer, 320
- Bile duct, metastatic disease to, palliative radiation therapy in, 160
- Biliary obstruction, palliation of, 176
- Biomarker
in lung cancer screening, 265
in non-small cell lung cancer, 281-282
- Bisacodyl, 182
- Bladder cancer, palliative radiation therapy in, 161
- Bloom's syndrome
colorectal cancer risk and, 12
genetics of, 19
- Bone, metastatic disease to, 156
- Brain, metastatic disease to, 158-159
- BRCA1, 19
- Breast-colon cancer syndrome, 19
- Bridge Program, 147, 148
- Bronchioloalveolar carcinoma, 251
chemotherapy, 330-331
clinical features, 329
epidemiology, 329-330
etiology, 330
histology, 328-329
molecular targeted therapy, 331-333
prognostic factors, 330
- Bronchoscopy, in lung cancer screening, 259
autofluorescence bronchoscopy, 254
fluorescence bronchoscopy, 262
- Bystander effect, 91
- C fiber, 198
- Cachexia, 202-204
pharmacologic agents for, 201
- Calcitonin, 187, 189
- Calcium
chemoprevention trial and, 26
in colorectal cancer, 29-30
- Canary pox, 80
- Cancer
cell cycle progression in
p14^{ARF}/mdm2/p53 pathway, 454-455
pRB/p16^{INK4a}/cyclin D1 pathway, 452-454
gene therapy, see Cancer gene therapy
genetic testing for, 215
immunotherapy, see Cancer immunotherapy
immunotoxins for, 591-594
multidrug resistant, see Multidrug resistant cancer
stages of, 222-224
virotherapy, see Oncolytic virotherapy
- Cancer epigenetics
aberrant DNA methylation, causes of
accelerating factors, 525-526
gene expression factor, 526
seed and spread model, 525
selective advantage, 526-527
clinical implications, 527-528
- Cancer epigenetics (Continued)
DNA methylation, 521
histone changes, 522
histone code, 526
hypermethylation of tumor-suppressor genes, 522-523
hypomethylation, 523-524
mutations of epigenetic effectors, 527
recruitment of epigenetic effector genes, 527
RNA interference, 522
tissue-specific methylation, 524
tumor-specific methylation, 525
- Cancer gene therapy, 535-536
adenoviral vectors for, 573-575
adverse outcomes, 580
clinical applications, 576
gene replacement therapy, 578-579
immunotherapy and, 576-578
oncolytic virotherapy, 579-580
suicide gene therapy, 578
targeting of, 575-576
antisense oligonucleotides for
Bcl-2 inhibition by, 568-569
cellular internalization, 564-565
chemically synthesized, properties of, 564
clinical utility of phosphodiester oligonucleotides, 563-564
pharmacokinetics, 566-569
phosphorothioate oligonucleotides, 565-566
second-generation oligonucleotides, pharmacokinetics, 568
for multidrug resistant cancer
antisense oligonucleotides for, 584-585, 587
characteristics, 583-584
clinical considerations, 587-588
clinical trials, 588
DNAzymes in, 587
"hybrid" transcriptional repressors in, 586-587
ribozymes for, 585, 587
RNA interference in, 586
transcriptional decoys in, 586
triple-forming oligonucleotides for, 585-586
- Cancer immunotherapy
and adenoviral vectors for cancer gene therapy, 576-578
genetically modified dendritic cell vaccines with tumor antigens, 556
clinical trials, 557-559
preclinical studies, 557
problems with clinical development, 559-560
rationale, 557
immunotoxins for, 591-594
poxviral vaccines for, 549
CEA and, 550-552
costimulation into, 551-552
PSA and, 550, 552-553
tumor-associated antigens and, 550-553
- Cancer management, WHO model of, 135
- Cancer pain, interventional, 194-195
- Cancer pain relief
approaches to, 180
clinical strategy for, 180-181
pharmacology for, 181-184
- Cancer pain syndrome, treatment of, 187
- Cancer rehabilitation
efficacy of, 220-221
goals of, 221-222
- Cancer screening
lung cancer, 259-266
non-small cell lung cancer, 251, 253-257
- Cancer staging
mediastinal lymph node metastasis, 269-276
non-small cell lung cancer, 251
- Cancer survivors, organizations for, 216-217

- Cancer testis antigens
 and epigenetic immunotherapy of solid tumors, 474
 in hematopoietic malignancies
 expression of, 516-517
 as potential *in vivo* targets of demethylating agents, 515-516
- CAP chemotherapy regimen, in non-small cell lung cancer, 279
- Capecitabine, 98
 adjuvant, 44-46
 in combination therapy, for colorectal cancer, 46-50
 irinotecan plus, in colorectal cancer, 48, 49
 oral, in colorectal cancer, 43-44
 oxaliplatin plus, in colorectal cancer, 46, 47, 49
 radiation plus, in rectal cancer, 49-50, 106
- Carbamazepine, 187, 189
- Carboplatin, docetaxel chemotherapy regimen, in non-small cell lung cancer, 301-302
- Carboplatin, etoposide chemotherapy regimen, in non-small cell lung cancer, 289-291
- Carboplatin, gemcitabine chemotherapy regimen, in non-small cell lung cancer, 300, 302
- Carboplatin, paclitaxel chemotherapy regimen, in non-small cell lung cancer, 281, 287-289, 301-302, 306, 308
- Carcinoembryonic antigen (CEA)
 and poxviral vaccines
 in cancer immunotherapy, 550-552
 vaccines and, 76-77
- Catheter, in direct drug delivery, 195-196
- CD34⁺ progenitor cells, in myelofibrosis with myeloid metaplasia, 386-388
- CEA, *see* Carcinoembryonic antigen
- Celecoxib, 183
 chemoprevention trial of, 26
 in colorectal cancer, 65, 66
 in combination therapy, for colorectal cancer, 73
- Celiac plexus neurolysis, 176
- Cell cycle, progression in cancer
 p14^{ARF}/mdm2/p53 pathway, 454-455
 pRB/p16^{INK4a}/cyclin D1 pathway, 452-454
- Celastrol, in non-small cell lung cancer, 323
- Central nervous system metastasis, in non-small cell lung cancer, 293-296
 prophylactic cranial irradiation, 293-296
- Cetuximab, 54-55, 109, 117
 for chemotherapy in non-small cell lung cancer, 317-318
 clinical development of, 55-56
- CHART, *see* Continuous hyperfractionated accelerated radiation therapy
- Chemical neurolysis, 196
- Chemoprevention, in lung cancer, 265
- Chemoradiation, 103-104
 in rectal cancer, 49-59
- Chemotherapy
 adjuvant
 in colorectal cancer, 96-99
 hepatic artery infusion, 89-90
 in non-small cell lung cancer, 251, 279-283
 uracil tegafur, in lung adenocarcinoma, 281
 aflinib, in non-small cell lung cancer, 320
 bevacizumab, in non-small cell lung cancer, 321
 bexarotene, in non-small cell lung cancer, 320
 in bronchioloalveolar carcinoma, 330-331
 cetuximab, in non-small cell lung cancer, 317-318
 combination, in non-small cell lung cancer, 284-291, 299-312
 consolidation, in non-small cell lung cancer
 docetaxel, 288-289
 paclitaxel, 290
 cytotoxic, in non-small cell lung cancer, 299-312
 epigenetic, *see* Chemotherapy, epigenetic
 erlotinib, in non-small cell lung cancer, 318-319
 gefitinib, in non-small cell lung cancer, 318-319
 gemcitabine monotherapy, in non-small cell lung cancer, 309
 induction, for non-small cell lung cancer, 284-291
- Chemotherapy (Continued)
 induction cisplatin, for non-small cell lung cancer, 286-287
 irinotecan monotherapy, in non-small cell lung cancer, 301
 lonafarnib, in non-small cell lung cancer, 319
 in malignant pleural mesothelioma, 336-341
 monotherapy v combination, in non-small cell lung cancer, 304-305
 neovastat, in non-small lung cancer, 320
 nonplatinum-based doublets, in non-small cell lung cancer, 302-304
 paclitaxel monotherapy, non-small cell lung cancer, 308-309
 palliative, *see* Palliative chemotherapy
 phase I trials of, 152-154
 platinum-based doublets, in non-small cell lung cancer, 300-302
 plus hyperfractionated accelerated radiation therapy, in non-small cell lung cancer, 287-288
 plus hyperfractionated radiation therapy
 in non-small cell lung cancer, 287
 v thoracic radiotherapy, in non-small cell lung cancer, 287-288, 290-291
 plus radiotherapy, in non-small cell lung cancer, 286-291
 plus surgery and radiotherapy, in non-small cell lung cancer, 284-285
 prinomastat, in non-small cell lung cancer, 320
 in refractory non-small cell lung cancer, 306-307
 in relation to age, 308-310
 retinoids, in non-small cell lung cancer, 320
 semaxanib, in non-small cell lung cancer, 321
 tipifarnib, in non-small cell lung cancer, 319
 trastuzumab, in non-small cell lung cancer, 319
 v continuous hyperfractionated accelerated radiation therapy, in non-small cell lung cancer, 287
 vinorelbine monotherapy, in non-small cell lung cancer, 300, 308-309
- Chemotherapy, epigenetic
 azacitidine in
 combinations with histone deacetylase inhibitors, 461
 dose-schedule optimization of, 459-460
 restoring or enhancing sensitivity to other therapy, 460-461
- decitabine in
 for acute myelogenous leukemia, 468-469
 antineoplastic activity in animal models, 445-446
 apoptosis activation by, 466
 background of, 437-438
 cellular pharmacology of, 444-445
 chemotherapy resensitization by, 466-467
 for chronic myelogenous leukemia, 469-470
 combinations with histone deacetylase inhibitors, 461
 dose-schedule optimization of, 447-449, 459-460
 drug resistance of, 445
 enzyme DNA adduct formation by, 466
 genomic hypomethylation by, 466
 hematopoietic toxicity of, 446-447
 history of, 438-440, 465
 induction of tumor-associated antigens by, 466
 mechanism of action, 466
 metabolism and molecular mechanism of action, 443-444
 for myelodysplastic syndrome, 468
 optimizing silenced gene reexpression with, 470
 pharmacokinetics of, 447
 phase I and II studies, 446
 present studies of, 440-441
 recent phase I clinical trials of, 467
 reduced telomerase activity by, 466
 restoring or enhancing sensitivity to other therapy, 460-461
 for solid tumors, 470
 for lung cancer, 488-499
 chromatin remodeling agents, 493-498
 for myeloid neoplasms
 cancer testis antigens and, 515-517
 low-dose azanucleosides, 511-512
in vivo markers of demethylation, 512-515
- Chemotherapy resensitization, by decitabine in epigenetic cancer therapy, 466-467

- Chest roentgenogram, in non-small cell lung cancer screening, 254-257
- CHOICES, 147, 148
- Choline Mg trisilicyle, 187
- Chromatin remodeling agents, for epigenetic lung cancer therapy, 488-499
- clinical trials of, 497-498
 - for lung cancer prevention, 498
 - preclinical studies of, 493-497
- Chromoendoscopy, 25
- Chromosomal abnormalities, in myeloid metaplasia with myelofibrosis
- chromosome 1, 360
 - chromosome 8, 360
 - chromosome 9, 360
 - chromosome 13, 360-361
 - chromosome 20, 361
- Chromosomal instability, 124
- Chromosome 18q, 125
- Chronic idiopathic myelofibrosis, *see* Myelofibrosis with myeloid metaplasia
- Chronic myelogenous leukemia, clinical development program of decitabine for, 469-470
- CI-1033, clinical development of, 55, 57
- Cisplatin, docetaxel chemotherapy regimen, in non-small cell lung cancer, 301-302
- Cisplatin, doxorubicin, cyclophosphamide chemotherapy regimen, in non-small cell lung cancer, 279
- Cisplatin, etoposide chemotherapy regimen, in non-small cell lung cancer, 309
- adjuvant chemotherapy, 280-281
 - induction chemotherapy, 285-286, 288-289
- Cisplatin, gemcitabine, vinorelbine chemotherapy regimen, in non-small cell lung cancer, 303-305
- Cisplatin, gemcitabine chemotherapy regimen, in non-small cell lung cancer, 300-302
- induction chemotherapy, 288
- Cisplatin, ifosfamide, mitomycin chemotherapy regimen, in non-small cell lung cancer, 284
- Cisplatin, induction chemotherapy, in non-small cell lung cancer, 286-287
- Cisplatin, irinotecan chemotherapy regimen, in non-small cell lung cancer, 301
- Cisplatin, paclitaxel chemotherapy regimen, in non-small cell lung cancer, 302, 309
- induction chemotherapy, 288
- Cisplatin, pemetrexed chemotherapy regimen, in malignant pleural mesothelioma, 340-341
- Cisplatin, vinblastine, mitomycin chemotherapy regimen, in non-small cell lung cancer, 306
- induction chemotherapy, 287
- Cisplatin, vinblastine chemotherapy regimen, in non-small cell lung cancer, 286-287
- Cisplatin, vindesine, mitomycin chemotherapy regimen, in non-small cell lung cancer, 280-281
- Cisplatin, vindesine chemotherapy regimen, in non-small cell lung cancer, 284-285, 300-301, 308
- Cisplatin, vinorelbine chemotherapy regimen, in non-small cell lung cancer, 301-302, 308
- adjuvant chemotherapy, 281
 - induction chemotherapy, 288
- Clinical features, of bronchioloalveolar carcinoma, 329
- Clonazepam, 187, 189
- Codeine, 182, 183-184
- Colon-breast cancer syndrome, 19
- Colonic obstruction, palliation of, 175
- Colonoscopy
- for colorectal cancer, 5-6
 - virtual, 8
- Colorectal cancer
- alarm symptoms for, 4
 - average-risk patients for, 5, 6
 - chemoprevention trials in, 26
 - colonoscopy for, 5-6
 - first-line therapy in, 35-37
 - genetic model in, 11-13
- Colorectal cancer (*Continued*)
- hepatic metastases of, hepatic resection for, 85-86
 - high-risk patients for, 4
 - incidence of, 1, 3, 24
 - inherited syndromes with risk of, 12
 - intermediate-risk patients for, 4-5
 - Knudson hypothesis of, 13
 - overview of, 1
 - recognizing hereditary syndromes of, 13
 - risk stratification for, 3-4
 - screening recommendations for, 5
 - second-line chemotherapy in, 40
 - stage II, adjuvant therapy for, 99-100
 - staging of, 95-96
 - two hit hypothesis of, 13
- Combination chemotherapy, v monotherapy, in non-small cell lung cancer, 304-305
- Combined modality therapy
- in non-small cell lung cancer, 279-291, 293-296
 - chemotherapy plus fractionated radiation therapy v thoracic radiotherapy, 287-288, 290-291
 - chemotherapy plus hyperfractionated accelerated radiation therapy, 287-288
 - chemotherapy plus radiotherapy, 280, 286-291
 - chemotherapy plus surgery, 280-281
 - chemotherapy plus surgery and radiotherapy, 284-285
 - for rectal cancer, 103-104
- Communication
- of bad news, 141-142
 - facilitating, 142-143
 - goals of, in clinical practice, 140
 - information provided in, 141-142
 - misconceptions about, 139-140
 - physician-patient, 140
 - as therapeutic tool, 139
- Complications, long-term, of splenectomy for myelofibrosis with myeloid metaplasia, 406-407
- Comprehensive Care Team Model, 147, 148
- Computed tomography
- high-resolution computed tomography, 259, 262
 - low-dose spiral computed tomography, 256-257, 261-262
 - in lung cancer screening, 254, 256-257, 259, 261-262
 - of malignant pleural mesothelioma, 336-337
 - positron emission tomography, 262, 271, 275-276
 - staging of mediastinal lymph node metastasis, 270-271, 273
- Confocal microscopy, in lung cancer screening, 263
- Constipation, management of, 182
- Continuous hyperfractionated accelerated radiation therapy, v chemotherapy, in non-small cell lung cancer, 287
- Conventional therapy, for myelofibrosis with myeloid metaplasia, 423-424
- Corticosteroid
- for anorexia, 201
 - as coanalgesic, 188-189
- COX-2, 26-27, 183
- in colorectal cancer, 70
 - colorectal polyps and, 71-72
- COX-2 inhibition
- colorectal polyposis and, 72
 - in combined modality therapy, for rectal cancer patient, 108-109
 - with cytotoxic chemotherapy, 72-73
 - preclinical effects of, 70-71
- Cranial irradiation, prophylactic, in central nervous system metastasis, 293-296
- Cryoablation, of colorectal cancer hepatic metastases, 87
- Cryoneurolysis, 196
- Cryotherapy
- definition of, 172
 - in thermal ablation, 172-173
- Cutaneous malignancies, aberrant DNA methylation in basal cell carcinoma, 480-481

- Cutaneous malignancies, aberrant DNA methylation in (*Continued*)
 lymphoma, 483-484
 melanoma, 481-483
 relationship with exposure to ultraviolet radiation, 484
 squamous cell carcinoma, 480-481
- Cyclooxygenase, 26, 69-70
- Cyclooxygenase-2 agents, 183
- Cyclooxygenase-2 inhibitors, in non-small cell lung cancer, 323
- Cyclophosphamide, doxorubicin, cisplatin chemotherapy regimen, in non-small cell lung cancer, 279
- Cytokines, involvement in pathogenesis of myelofibrosis and osteosclerosis in mouse models, 368-370
- Cytosine deaminase gene, in prodrug therapy, 91-92
- Cytoreductive therapy, for myelofibrosis with myeloid metaplasia, 424
- Cytotoxic chemotherapy, in non-small cell lung cancer, 299-312
 carboplatin, docetaxel regimen, 301-302
 carboplatin, gemcitabine regimen, 300, 302
 carboplatin, paclitaxel regimen, 301-302, 306, 308
 cisplatin, docetaxel regimen, 301-302
 cisplatin, etoposide regimen, 309
 cisplatin, gemcitabine, vinorelbine regimen, 303-305
 cisplatin, gemcitabine regimen, 300, 301-302
 cisplatin, irinotecan regimen, 301
 cisplatin, paclitaxel regimen, 302, 309
 cisplatin, vindesine regimen, 300, 301, 308
 cisplatin, vinorelbine regimen, 301-302, 308
 docetaxel, gemcitabine regimen, 303, 308
 gemcitabine, vinorelbine regimen, 303, 308-309
 gemcitabine monotherapy, 309
 ifosfamide, vinorelbine regimen, 303-304
 irinotecan monotherapy, 301
 mitomycin, vinblastine, cisplatin regimen, 306
 paclitaxel, gemcitabine regimen, 303, 309
 paclitaxel monotherapy, 308-309
 in relation to age, 308-310
 vinorelbine monotherapy, 300, 308-309
- Decitabine
 in epigenetic cancer therapy
 activation of apoptotic pathways, 466
 for acute myelogenous leukemia, 468-469
 antineoplastic activity in animal models, 443-446
 background of, 437-438
 cellular pharmacology of, 444-445
 chemotherapy resensitization, 466-467
 for chronic myelogenous leukemia, 469-470
 combinations with histone deacetylase inhibitors, 461
 dose-schedule optimization of, 447-449, 459-460
 drug resistance of, 445
 enzyme DNA adduct formation, 466
 genomic hypomethylation, 466
 hematopoietic toxicity of, 446-447
 history of, 438-440, 465
 induction of tumor-associated antigens, 466
 mechanisms of action, 466
 metabolism and molecular mechanism of action, 443-444
 for myelodysplastic syndrome, 468
 for myeloid neoplasms, 511-512
 optimizing silenced gene reexpression, 470
 pharmacokinetics of, 447
 phase I and II studies, 446
 present studies of, 440-441
 recent phase I clinical trials, 467
 reduced telomerase activity, 466
 restoring or enhancing sensitivity to other therapy, 460-461
 for solid tumors, 470
 for myelofibrosis with myeloid metaplasia, 427
- Dehydration, following sedation, 241
- Delayed type hypersensitivity testing, 78
- Dendritic cell vaccines, genetically modified with tumor antigens, 556
 clinical trials
 DNA-transfected dendritic cells, 559
 RNA-transfected dendritic cells, 557-559
 preclinical studies, 557
 problems with clinical development, 559-560
 rationale, 557
- Deoxycholate, 53
- Depression, treatment of, 212-214
- Desipramine, 187, 189
- Dexamethasone, 187, 203
- Diagnosis, *see also* Differential diagnosis
 of extramedullary hematopoiesis, in myelofibrosis with myeloid metaplasia, 404
 of myelofibrosis with myeloid metaplasia, 396-398
- Differential diagnosis, of myelofibrosis with myeloid metaplasia, 388-389
- Difluoromethylornithine, 28-29
- Chemoprevention trial of, 26
- Dihydropyrimidine dehydrogenase, 114-115, 122
- Dissection, mediastinal lymph node, for staging of cancer metastasis, 274-275
- Distress
 impairment-associated psychological, 220
 treatment of, 214-215
- dl1520 (ONYX-015), for oncolytic virotherapy, clinical trial results, 542-543
- DNA hypomethylating agents, immunomodulatory activity of, 475-477
- DNA hypomethylation, in cancer, 523-524
- DNA methylation, in cancer
 aberrant, *see* Aberrant DNA methylation
 tissue-specific, 524
 tumor-specific, 525
- DNA methylation inhibitors, *see* Azacitidine; Decitabine; DNA hypomethylating agents
- DNA mismatch repair system, 25
- DNA testing, stool-based, 8-9
- DNA-transfected dendritic cells, for cancer immunotherapy, clinical trials, 559
- DNAzymes, in multidrug cancer gene therapy, 587
- Docetaxel, carboplatin chemotherapy regimen, in non-small cell lung cancer, 301-302
- Docetaxel, cisplatin chemotherapy regimen, in non-small cell lung cancer, 301-302
- Docetaxel, gemcitabine chemotherapy regimen, in non-small cell lung cancer, 303, 308
- Docetaxel consolidation chemotherapy, in non-small cell lung cancer, 288-289
- Docusate sodium, 182
- Dose-schedule optimization, of decitabine in epigenetic cancer therapy, 447-449, 459-460
- Double-contrast barium enema, 7-8
- Douillard regimen, 35
- Doxorubicin, cyclophosphamide, cisplatin chemotherapy regimen, in non-small cell lung cancer, 279
- Dronabinol, 203
 for anorexia, 201
- Drug delivery
 in cancer pain, 195
 direct, 195-196
 plexus, 196
- Drug resistance
 to decitabine in epigenetic cancer therapy, 445
 multiple, in cancer, *see* Multidrug resistance cancer
- Dukes classification, of colorectal cancer, 96
- Dysphagia, malignant, palliation of, 175
- Dyspnea
 definition of, 204
 management of, 205-206
 prevalence of, 205
- EBUS, *see* Endobronchial ultrasound
- Edotecarin, in colorectal cancer, 39
- Edrecolomab, 99

- Efformithine, 28-29
 EGFR, *see* Epidermal growth factor receptor
 EGFR-tyrosine kinase inhibitors, in malignant pleural mesothelioma, 342-343
 EKB-569, clinical development of, 55, 57
 Elderly
 adjuvant chemotherapy in, for colorectal cancer, 100
 first-line colorectal cancer therapy and, 38
 Emperipoleis, abnormal, role in cytokine release and pathogenesis of myelofibrosis, 369-370
 Endobronchial ultrasound, staging of mediastinal lymph node metastasis, 272, 275
 Endo-esophageal ultrasound fine-needle aspiration, staging of mediastinal lymph node metastasis, 272
 Endoscopic obstruction, palliation of, 175
 Endoscopic retrograde cholangiopancreatography, 176
 Endoscopic ultrasound, 174
 Enema, phosphate soda, 182
 Enteral obstruction, definition and palliation of, 175
 Enzyme DNA adduct formation, and decitabine in epigenetic cancer therapy, 466
 Enzyme-linked immunospot assay, 78
 Epidemiology, bronchioloalveolar carcinoma, 329-330
 Epidermal growth factor
 in colorectal cancer growth, 53-54
 in colorectal cancer tumorigenesis, 52-53
 as prognostic factor, in colorectal cancer, 54
 strategies targeting, 54-55
 Epidermal growth factor receptor, inhibitor of, in colorectal cancer, 109
 Epidermal growth factor receptor inhibition, in non-small cell lung cancer, 316-317
 Epigenetic alterations, in lung cancer screening, 264
 Epigenetic cancer therapy
 azacitidine in
 combinations with histone deacetylase inhibitors, 461
 dose-schedule optimization, 459-460
 restoring or enhancing sensitivity to other therapy, 460-461
 decitabine in
 for acute myelogenous leukemia, 468-469
 antineoplastic activity in animal models, 445-446
 apoptosis activation by, 466
 background of, 437-438
 cellular pharmacology, 444-445
 chemotherapy resensitization by, 466-467
 for chronic myelogenous leukemia, 469-470
 combinations with histone deacetylase inhibitors, 461
 dose-schedule optimization, 447-449, 459-460
 drug resistance, 445
 enzyme DNA adduct formation by, 466
 genomic hypomethylation by, 466
 hematopoietic toxicity, 446-447
 history of, 438-440, 465
 induction of tumor-associated antigens, 466
 mechanisms of action, 466
 metabolism and molecular mechanism of action, 443-444
 for myelodysplastic syndrome, 468
 optimizing silenced gene reexpression with, 470
 pharmacokinetics, 447
 phase I and II studies, 446
 present studies of, 440-441
 recent phase I clinical trials, 467
 reduced telomerase activity by, 466
 restoring or enhancing sensitivity to other therapy, 460-461
 for solid tumors, 470
 immunotherapy, *see* Epigenetic immunotherapy
 for lung cancer, 488-499
 chromatin remodeling agents, 493-498
 for myeloid neoplasms
 cancer testis antigens and, 515-517
 low-dose azanucleosides, 511-512
 Epigenetic cancer therapy (*Continued*)
 in vivo markers of demethylation, 512-515
 Epigenetic immunotherapy
 for hematopoietic malignancies
 Hodgkin's lymphoma, 506
 multiple myeloma, 506-507
 myeloproliferative disorders, 507-508
 non-Hodgkin's lymphoma, 504-505
 primary effusion lymphoma, 505
 for solid tumors
 cancer testis antigens and, 474
 DNA hypomethylating agents for, 475-477
 HLA antigens and, 475-476
 Epigenetics, in cancer, *see* Cancer epigenetics
 EPO, *see* Erythropoietin
 Epithelones, in colorectal cancer, 39
 Epstein-Barr virus genomic DNA, as in vivo marker of demethylation for myeloid neoplasms, 514-515
 Erlotinib, 109
 clinical development of, 55-57
 in non-small cell lung cancer, 318-319
 Erythropoietin, for myelofibrosis with myeloid metaplasia, 423-424
 Esophageal cancer, palliative radiation therapy in, 160
 Esophageal obstruction, palliation in, 175
 Etanercept, for myelofibrosis with myeloid metaplasia, 427-428
 Ethanol, percutaneous infiltration of, in metastatic colorectal cancer, 88
 Etiology, bronchioloalveolar carcinoma, 330
 Etoposide
 carboplatin chemotherapy regimen, in non-small cell lung cancer, 289-291
 cisplatin chemotherapy regimen, in non-small cell lung cancer, 309
 adjuvant chemotherapy, 280-281
 induction chemotherapy, 285-286
 Euthanasia, v sedation, 239-240
 External-beam radiation therapy
 palliative, 156-158
 for extramedullary hematopoiesis in myelofibrosis with myeloid metaplasia, 408
 for respiratory symptoms, 159
 Extramedullary hematopoiesis, in myelofibrosis with myeloid metaplasia
 abdominal radiation for, 408-410
 diagnosis and imaging of, 404
 external beam radiotherapy for, 408
 liver radiation for, 408-410
 lung radiation for, 410
 origin of, 404
 spinal/paraspinal, 410
 splenic radiation for, 408
 surgical management of, 405
 symptomatic, medical palliation of, 405
 Facing Our Risk of Cancer Empowered, 216
 Familial adenomatous polyposis
 colorectal cancer risk and, 4, 12
 genetics of, 13-15
 genotype-phenotype correlations in, 15
 Farnesyl transferase inhibitors, in non-small cell lung cancer, 319
 Fatigue, cancer-related, 200-201
 Fecal occult blood testing, 6-7
 Fentanyl, 182, 183-184
 Fetal hemoglobin expression, as in vivo marker of demethylation for myeloid neoplasms, 515
 Fibrogenic growth factors, and their receptors, in stem cell dysregulation in myelofibrosis with myeloid metaplasia, 374-375
 Flexible sigmoidoscopy, 7
 Fluorescence bronchoscopy, in lung cancer screening, 262
 Fluoropyrimidine regimens
 in colorectal cancer, 44
 survival after, 50
 safety of, 46

- Fluorouracil, 113-114
 in chemoradiation regimen, for rectal cancer, 103-104
 in combination chemotherapy, for colorectal cancer, 96-99
- Folate, chemoprevention trial and, 26
- FOLFIRI regimen, 49, 100-101
 trials of, 36, 40
- FOLFOX regimen, 98-100
 in colorectal cancer, 47
 trials of, 36, 40
- Folic acid, in colorectal cancer, 30
- Gabapentin, 187, 189
- Gamma camera techniques, in lung cancer screening, 263
- Ganciclovir, 92
- GATA-1 expression, role in pathogenesis of myelofibrosis and osteosclerosis in mouse models, 367-369
- Gefitinib, 109
 clinical development of, 55-56
 in non-small cell lung cancer, 318-319
- Gemcitabine, carboplatin chemotherapy regimen, in non-small cell lung cancer, 300, 302
- Gemcitabine, cisplatin, vinorelbine chemotherapy regimen, in non-small cell lung cancer, 303-305
- Gemcitabine, cisplatin chemotherapy regimen, in non-small cell lung cancer, 300, 301-302
 induction chemotherapy, 288
- Gemcitabine, docetaxel chemotherapy regimen, in non-small cell lung cancer, 303, 308
- Gemcitabine, paclitaxel chemotherapy regimen, in non-small cell lung cancer, 303, 309
- Gemcitabine, vinorelbine chemotherapy regimen, in non-small cell lung cancer, 303, 308-309
- Gemcitabine monotherapy, in non-small cell lung cancer, 309
- Gene deletion mutants, use in oncolytic virotherapy
 apoptosis inhibition and, 539-540
 immune effectors and, 540
 interferon pathway inhibition and, 540
 p53 pathway inhibition and, 539-540
 PKR pathway inhibition and, 540
 S-phase induction and, 539
- Gene therapy, for cancer, see Cancer gene therapy
- Gene-directed enzyme prodrug therapy, 91-92
- Genetic alterations, in lung cancer screening, 263-264
- Genetic testing, for cancer, 215
- Genetic translocations, balanced, in myelofibrosis with myeloid metaplasia, 361
- Genetics, in lung cancer screening
 epigenetic alterations, 264
 genetic alterations, 263-264
 genetic predisposition, 261
 genomic instability, 264
 molecular profiling, 264
- GFB-111, in malignant pleural mesothelioma, 343
- Gleevec, in malignant pleural mesothelioma, 343
- GW572016, clinical development of, 55, 57
- Gynecologic cancer, palliative radiation therapy in, 161
- HART, see Hyperfractionated accelerated radiation therapy
- Head and neck cancer, palliative radiation therapy in, 161
- Heat shock protein, 79, 97
- Heating, in thermal ablation, 172-173
- Hematologic neoplasms, clinical development of decitabine for
 acute myelogenous leukemia
 combination therapy, 469
 monotherapy, 468-469
 chronic myelogenous leukemia, 469-470
 myelodysplastic syndrome, 468
- Hematopathologic findings, in myelofibrosis with myeloid metaplasia, 380-391
- Hematopoietic growth factors, and their receptors, in stem cell dysregulation in myelofibrosis with myeloid metaplasia, 374-375
- Hematopoietic neoplasms
 epigenetic immunotherapy for
 Hodgkin's lymphoma, 506
 multiple myeloma, 506-507
 myeloproliferative disorders, 507-508
 non-Hodgkin's lymphoma, 504-505
 primary effusion lymphoma, 505
 epigenetic therapy for myeloid neoplasms
 cancer testis antigens and, 515-517
 low-dose azanucleosides, 511-512
 in vivo markers of demethylation, 512-515
- Hematopoietic progenitors, and stromal interactions, in stem cell dysregulation in myelofibrosis with myeloid metaplasia, 375
- Hematopoietic toxicity, to decitabine in epigenetic cancer therapy, 446-447
- Hemoglobin expression, fetal, as in vivo marker of demethylation for myeloid neoplasms, 515
- Hemopoietic stem cell transplantation, for myelofibrosis with myeloid metaplasia, 414-420
 allogeneic, 414-419
 autologous, 419-420
- Hepatic artery infusional chemotherapy
 for colorectal cancer metastases, 89-90
 palliative, 90-91
- Hepatic resection, for hepatic metastases, of colorectal cancer, 85-86
- Hepatocyte growth factor/scatter factor, in malignant pleural mesothelioma, 344
- HER2 inhibition, in non-small cell lung cancer, 319
- Hereditary nonpolyposis colon cancer
 colorectal cancer risk and, 4, 12
 diagnosis of, clinical guidelines for, 16
 genetic testing algorithm for, 16
 genetics of, 15-17
 lifetime risks for, 15
- Herpes simplex virus thymidine kinase, in prodrug therapy, 91-92
- HGF/SF, see Hepatocyte growth factor/scatter factor
- High-resolution computed tomography, in lung cancer screening, 259, 262
- High-risk population, in lung cancer screening, 260-261
- Histology, bronchioloalveolar carcinoma, 328-329
- Histone deacetylase inhibitors, combination with DNA methylation inhibitors in epigenetic cancer therapy, 461
- Histopathology, and prognosis, of myelofibrosis with myeloid metaplasia, 389-391
- HLA antigens, and epigenetic immunotherapy of solid tumors, 475-476
- Hodgkin's lymphoma, epigenetic immunotherapy for, 506
- Hospice, 135
 historical perspective of, 146-147
- Hydrocodone, 182, 183-184
- Hydromorphone, 182, 183-184
- Hyosine, 207
- Hyperfractionated accelerated radiation therapy plus induction chemotherapy, in non-small cell lung cancer, 287-288
- Hyperfractionated radiation, in non-small cell lung cancer
 plus chemotherapy, 287
 v thoracic radiotherapy, 287-288, 290-291
- Hypermethylation, of tumor suppressor genes in cancer, 522-523
- Hyperplastic polyposis syndrome
 clinical diagnostic criteria for, 18-19
 colorectal cancer risk and, 12
 genetics of, 18-19
- Hypertension, portal, see Portal hypertension
- Hypnosis, 227-228
- Hypogastric plexus block, 198
- Ibuprofen, 187
- Idiopathic myelofibrosis, see Myelofibrosis, with myeloid metaplasia
- Ifosfamide, mitomycin, and cisplatin chemotherapy regimen, in non-small cell lung cancer, 284
- Ifosfamide, vinorelbine chemotherapy regimen, in non-small cell lung cancer, 303-304

- Imaging, of extramedullary hematopoiesis, in myelofibrosis with myeloid metaplasia, 404
- Imatinib mesylate, in malignant pleural mesothelioma, 343
- Immunotherapy, epigenetic
for hematopoietic malignancies
Hodgkin's lymphoma, 506
multiple myeloma, 506-507
myeloproliferative disorders, 507-508
non-Hodgkin's lymphoma, 504-505
primary effusion lymphoma, 505
for solid tumors
cancer testis antigens and, 474
DNA hypomethylating agents for, 475-477
HLA antigens and, 475-476
- Immunotoxin(s), for cancer, 591-594
- Indomethacin, 187
- Inflammatory bowel disease, colorectal cancer risk and, 4
- Investigational therapy, for myelofibrosis with myeloid metaplasia
antiangiogenic agents, 424-426
signal transduction inhibitors, 426-427
- Irinotecan
capecitabine plus, in colorectal cancer, 48, 49
in combined modality therapy, for rectal cancer, 106-107
drug pathway of, 115-116
monotherapy in non-small cell lung cancer, 301
response to, 124-125
trials of, 35-38, 40
- Irinotecan, cisplatin chemotherapy regimen, in non-small cell lung cancer, 301
- Juvenile polyposis syndrome
clinical diagnostic criteria for, 18
colorectal cancer risk and, 12
genetics of, 18
- Kaposi's sarcoma, AIDS-associated, palliative radiation therapy in, 161
- Ketamine, 244
- Ketorolac, 187
- Knudson, two hit hypothesis of, 13
- K-ras gene, 124
- Lactulose, 182
- Leflunomide, in malignant pleural mesothelioma, 343
- Leucovorin, in combination chemotherapy, for colorectal cancer, 96-99
- Levamisole, in combination chemotherapy, for colorectal cancer, 96-99
- Levorphanol, 182, 183-184
- Lidocaine, topical, 187, 189
- Lipiodol, 170
- Liver, metastatic disease to, palliative radiation therapy in, 160
- Liver radiation, for extramedullary hematopoiesis, in myelofibrosis with myeloid metaplasia, 408-410
- Living Beyond Breast Cancer, 216
- LKB1, 17-18
- Lonafarnib, in non-small cell lung cancer, 319
- Long-term complications, *see* Complications, long-term
- Low-dose azanucleosides, in epigenetic therapy of myeloid neoplasms, 511-512
- Low-dose spiral computed tomography
lung cancer screening, 261-262
non-small cell lung cancer screening, 256-257
- Low-fat diet, chemoprevention trial and, 26
- Lung adenocarcinoma, uracil tegafur adjuvant chemotherapy, 281
- Lung cancer
epigenetic therapy for, 488-499
chromatin remodeling agents, 493-498
non-small cell, 251-252
adjuvant chemotherapy, 279-283
central nervous metastasis, 293-296
chemoprevention, 265
combination chemotherapy, 284-291, 299-312
combined modality therapy, 279-291, 293-296
- Lung cancer (Continued)
consolidation chemotherapy, 288-290
cytotoxic chemotherapy, 299-312
effects of chemotherapy in relation to age, 308-310
induction chemotherapy, 284-291
mediastinal lymph node metastasis, 269-276
monotherapy v combination chemotherapy, 304-305
nonplatinum-based doublets in chemotherapy, 302-304
palliative treatment, 251
platinum-based doublets in chemotherapy, 300-302
refractory disease, 306-307
screening, 251, 253-257, 261
staging, 251
targeted therapy, 315-325
tumor-specific targeted therapy, 251
vaccine therapy in adjuvant chemotherapy, 282
palliative radiation therapy in, 159-160
screening
autofluorescence bronchoscopy, 254
biomarkers, 265
bronchoscopy, 259, 262
chest roentgenogram, 254-257
computed tomography, 254, 261-262
confocal microscopy, 263
epigenetic alterations, 264
fluorescence bronchoscopy, 259, 262
gamma camera techniques, 263
genetic alterations, 263-264
genetic predisposition, 261
genomic instability, 264
high-resolution computed tomography, 259, 262
high-risk population, 260-261
low-dose spiral computed tomography, 256-257, 261-262
magnetic resonance imaging, 263
matrix-assisted laser desorption ionization-mass spectroscopy, 265
molecular imaging, 263
molecular profiling, 264
near-infrared Raman spectroscopy, 263
optical coherence tomography, 263
positron emission tomography, 262
proteomic approach, 264-265
sputum cytology, 254-257, 260-261
- Lung radiation, for extramedullary hematopoiesis, in myelofibrosis with myeloid metaplasia, 410
- Lymph node mapping, sentinel, staging of mediastinal lymph node metastasis, 274-275
- Lymphadenectomy, staging of mediastinal lymph node metastasis, 274
- Lymphoma
cutaneous, aberrant DNA methylation in, 483-484
primary effusion, epigenetic immunotherapy for, 505
- M.D. Anderson Cancer Center, palliative medicine in, 137
- Magnesium citrate, 182
- Magnetic resonance imaging
lung cancer screening, 263
malignant pleural mesothelioma, 337
staging of mediastinal lymph node metastasis, 271
- MALDI-MS, *see* Matrix-assisted laser desorption ionization-mass spectroscopy
- Malignant dysphagia, palliation of, 175
- Malignant pleural mesothelioma, 251
anti-EGFR antibody therapy, 341-343
Avastin, 343-344
bevacizumab, 343-344
chemotherapy, 336-341
computed tomography, 336-337
EGFR-tyrosine kinase inhibitors, 342-343
GFB-111, 343
Gleevec, 343

- Malignant pleural mesothelioma, 251 (*Continued*)
 hepatocyte growth factor/scatter factor, 344
 imatinib mesylate, 343
 leflunomide, 343
 magnetic resonance imaging, 337
 mammalian target of rapamycin, 344
 molecular targeted therapy, 341-345
 onconase, 341
 pemetrexed, cisplatin regimen, 340-341
 pemetrexed treatment, 339-341
 platelet-derived growth factor receptor inhibitors, 343
 positron emission tomography, 337-338
 prognostic factors, 335-336
 proteasome/ubiquitin pathway, 344-345
 PTK 787, 343
 ranpirnase, 341
 response to chemotherapy, 336-338
 SU101, 343
 SU5416, 343
 SU11274, 344
 thalidomide, 343-344
 vascular endothelial growth factor inhibitors, 343-344
- Mammalian target of rapamycin, in malignant pleural mesothelioma, 344
- Manifest fibrotic stage, of myelofibrosis with myeloid metaplasia, 382-383
- Mass spectroscopy, matrix-assisted laser desorption ionization, in lung cancer screening, 265
- Massage, 228-229
- Matrix metalloproteinase inhibitors, in non-small cell lung cancer, 320
- Matrix-assisted laser desorption ionization-mass spectroscopy, in lung cancer screening, 265
- Mediastinal lymph node dissection, in metastasis staging, 274-275
- Mediastinal lymph node metastasis, in lung cancer
 computed tomography, 270-271, 273
 dissection, 274-275
 endobronchial ultrasound, 272, 275
 endo-esophageal ultrasound fine-needle aspiration, 272
 lymphadenectomy, 274
 magnetic resonance imaging, 271
 mediastinoscopy, 272-275
 mediastinotomy, 272-274
 positron emission tomography, 271, 275-276
 sentinel lymph node mapping, 274-275
 staging, 269-276
 transbronchial needle aspiration, 271-272
 video-assisted thoroscopic surgery, 273-274
- Mediastinoscopy, staging of mediastinal lymph node metastasis, 272-275
 complications and indications, 273
- Mediastinotomy, staging of mediastinal lymph node metastasis, 272-274
 complications and indications, 273
- Meditation, 228
- Megakaryocytes, role of abnormal emperipoiesis in pathogenesis of myelofibrosis, and cytokine release of, 369-370
- Megestrol acetate, 203
 for anorexia, 201
- Melanocytes, atypical capsular, 596-597
- Melanoma, cutaneous, aberrant DNA methylation in, 481-483
 relationship with exposure to ultraviolet radiation, 484
- Meperidine, 182, 183-184
- Mesmerism, 227
- Mesothelioma, malignant pleural, 251, 335-345
 anti-EGFR antibody therapy, 341-343
 Avastin, 343-344
 bevacizumab, 343-344
 chemotherapy, 336-341
 computed tomography, 336-337
 EGFR-tyrosine kinase inhibitors, 342-343
 GFB-111, 343
 Gleevec, 343
 hepatocyte growth factor/scatter factor, 344
 Mesothelioma, malignant pleural, 251, 335-345 (*Continued*)
 imatinib mesylate, 343
 leflunomide, 343
 magnetic resonance imaging, 337
 mammalian target of rapamycin, 344
 molecular targeted therapy, 341-345
 onconase, 341
 pemetrexed, cisplatin regimen, 340-341
 pemetrexed treatment, 339-341
 platelet-derived growth factor receptor inhibitors, 343
 positron emission tomography, 337-338
 prognostic factors, 335-336
 proteasome/ubiquitin pathway, 344-345
 PTK 787, 343
 ranpirnase, 341
 response to chemotherapy, 336-338
 SU101, 343
 SU5416, 343
 SU11274, 344
 thalidomide, 343-344
 vascular endothelial growth factor inhibitors, 343-344
- Metaplasia, myeloid, with myelofibrosis, see Myelofibrosis with myeloid metaplasia
- Metastasis
 central nervous system, 293-296
 mediastinal lymph node, 269-276
- Methadone, 182, 183-184, 188
- Methylprednisolone, 187
- Mexiletine, 187, 189
- Microsatellite instability, 25, 123-124
 in colorectal screening, 9
- Microscopy, confocal, in lung cancer screening, 263
- Microwave ablation, of colorectal cancer hepatic metastases, 87-88
- Midazolam, for extraordinary sedation, 243
- Milk of magnesia, 182
- Mind-body medicine, 227
- Mindfulness-based art therapy, 228
- Mindfulness-based stress reduction, 228
- Mitomycin, ifosfamide, cisplatin chemotherapy regimen, in non-small cell lung cancer, 284
- Mitomycin, vinblastine, cisplatin chemotherapy regimen, in non-small cell lung cancer, 306
 induction chemotherapy, 287
- Mitomycin, vindesine, cisplatin chemotherapy regimen, in non-small cell lung cancer, 280-281
- Molecular imaging, in lung cancer screening, 263
- Molecular profiling, in lung cancer screening, 264
- Molecular targeted therapy
 in bronchioloalveolar carcinoma, 331-333
 in malignant pleural mesothelioma, 341-345
 in non-small cell lung cancer, 315-325
- Monoclonal antibody therapy, in colorectal cancer, 99
- Monotherapy, in non-small cell lung cancer
 gemcitabine, 309
 irinotecan, 301
 paclitaxel, 308-309
 v combination chemotherapy, 304-305
 vinorelbine, 300
- Morphine, 182, 183-184
- Mouse models, pathogenesis of myelofibrosis with myeloid metaplasia, 365-370
- MRI, see Magnetic resonance imaging
- MTOR, see Mammalian target of rapamycin
- Multidrug resistant cancer, gene therapy for
 antisense oligonucleotides for, 584-585, 587
 characteristics, 583-584
 clinical considerations, 587-588
 clinical trials, 588
 DNAzymes in, 587
 "hybrid" transcriptional repressors in, 586-587

- Multidrug resistant cancer, gene therapy for (*Continued*)
 ribozymes for, 585, 587
 RNA interference in, 586
 transcriptional decoys in, 586
 triple-forming oligonucleotides for, 585-586
- Multiple myeloma, epigenetic immunotherapy for, 506-507
- MVP chemotherapy regimen, in non-small cell lung cancer, 280-281
- Myelodysplastic syndrome, clinical development program of decitabine for, 468
- Myelofibrosis with myeloid metaplasia, 357-358
 abdominal radiation for, 408-410
 androgens for anemia in, 423
 angiogenesis in, 385-386
 antiangiogenic agents for, 424-426
 balanced translocations in, 361
 CD34⁺ progenitor cells in, 386-388
 chromosomal abnormalities in
 chromosome 1, 360
 chromosome 8, 360
 chromosome 9, 360
 chromosome 13, 360-361
 chromosome 20, 361
 clinical consequences of myeloproliferation in, 404
 conventional therapy for, 423-424
 cytogenetic abnormalities and prognosis of, 361
 cytoreductive therapy for, 424
 decitabine for, 427
 diagnosis of, 396-398
 differential diagnosis of, 388-389
 erythropoietin for, 423-424
 etanercept for, 427-428
 extramedullary hematopoiesis in
 diagnosis and imaging of, 404
 external beam radiotherapy for, 408-410
 origin of, 404
 surgical management of, 405
 symptomatic, medical palliation of, 405
 genetic studies on, 361-362
 hematopathologic findings in, 380-391
 hemopoietic stem cell transplantation for, 414-420
 allogeneic, 414-419
 autologous, 419-420
 investigational therapy for, 424-427
 liver radiation for, 408-410
 lung radiation for, 410
 manifest fibrotic stage of, 382-383
 mouse models of, 365-370
 natural history and survival in, 398
 pathogenesis of, 365-370
 abnormal emperipoiesis in, 369-370
 cytokines in, 368-369
 GATA-1 expression in, 367-369
 thrombopoietin overexpression in, 366-367
 pirfenidone for, 427
 prefibrotic stage of, 381-382
 prognosis and histopathology of, 389-391
 prognostic factors and staging systems of, 399-401
 proliferation and apoptosis in, 383-385
 signal transduction inhibitors for, 426-427
 splenectomy for, 403-407
 splenic radiation for, 408
 stem cell dysregulation in, 373-377
 fibrogenic growth factors and their receptors in, 374-375
 hematopoietic growth factors and their receptors in, 374-375
 hematopoietic progenitors in, 375
 signaling in, 375-376
 stromal interactions in, 375
 transcription factors in, 375-376
 surgery and radiotherapy for, 403-411
 surgical palliation of portal hypertension in, 408
- Myelogenous leukemia
 acute, *see* Acute myelogenous leukemia
 chronic, *see* Chronic myelogenous leukemia
- Myeloid metaplasia with myelofibrosis, *see* Myelofibrosis with myeloid metaplasia
- Myeloid neoplasms, epigenetic therapy for
 cancer testis antigens and
 expression in neoplasms, 516-517
 as potential in vivo targets, 515-516
 low-dose azanucleosides, 511-512
 in vivo markers of demethylation, 512-515
 Epstein-Barr virus genomic DNA, 514-515
 fetal hemoglobin expression, 515
 p15/INK4B, 514
- Myeloproliferation, in myelofibrosis with myeloid metaplasia, clinical consequences of, 404
- Myeloproliferative disorders, epigenetic immunotherapy for, 507-508
- MYH polyposis syndrome
 colorectal cancer risk and, 12
 genetics of, 17
- Myoclonus, treatment of, 206-207
- Nabumetone, 187
- Nandrolone, 204
- National Alliance of Breast Cancer Organizations, 216
- National Cancer Institute, 216
- Natural history, and survival, in myelofibrosis with myeloid metaplasia, 398
- Near-infrared Raman spectroscopy, in lung cancer screening, 263
- Needle aspiration, transbronchial, staging of mediastinal lymph node metastasis, 271-272
- Neovastat, in non-small cell lung cancer, 320
- Neural blockade, 196-197
- Neuro-emotional technique, 227
- Neurolysis, peripheral, 197-198
- Neurostimulation, definition of, 198
- Non-Hodgkin's lymphoma, epigenetic immunotherapy for, 504-505
- Nonplatinum-based doublets, in non-small cell lung cancer, 302-304
 cisplatin, gemcitabine, vinorelbine regimen, 303-305
 docetaxel, gemcitabine regimen, 303, 308
 gemcitabine, vinorelbine regimen, 303, 308-309
 ifosfamide, vinorelbine regimen, 303-304
 paclitaxel, gemcitabine regimen, 303, 309
 in relation to age, 308-310
- Non-small cell lung cancer, 251-252
 adjuvant chemotherapy, 279-283
 central nervous system metastasis, 293-296
 chemoprevention, 265
 combination chemotherapy, 284-291, 299-312
 combined modality therapy, 279-291, 293-296
 consolidation chemotherapy, 288-290
 cytotoxic chemotherapy, 299-312
 effects of chemotherapy in relation to age, 308-310
 induction chemotherapy, 284-291
 mediastinal lymph node metastasis, 269-276
 monotherapy v combination chemotherapy, 304-305
 nonplatinum-based doublets in chemotherapy, 302-304
 palliative chemotherapy in, 150-152
 palliative treatment, 251
 platinum-based doublets in chemotherapy, 300-302
 refractory disease, 306-307
 screening, 251, 253-257, 261
 staging, 251
 targeted therapy, 315-325
 tumor-specific targeted therapy, 251
 vaccine therapy in adjuvant chemotherapy, 282
- Nonsteroidal anti-inflammatory drugs
 antitumor effects of, 26-27
 colorectal cancer and, 25-28

- Nortriptylene, 187, 189
- Nucleic acid vaccine, trials of, 79-80
- Nurse case management, in palliative medicine, 136
- Octreotide, 187, 190
- Ocular metastasis, palliative radiation therapy in, 161
- Oligonucleotides
- antisense, *see* Antisense oligonucleotides
 - phosphodiester, *see* Phosphodiester oligonucleotides
 - phosphorothioate, *see* Phosphorothioate oligonucleotides
 - second-generation, *see* Second-generation oligonucleotides
 - triple-forming, *see* Triple-forming oligonucleotides
- Omega-3 fatty acids, for anorexia, 201
- Oncogene inactivation, antisense oligonucleotides for
- Bcl-2 inhibition and, 568-569
 - cellular internalization, 564-565
 - chemically synthesized, properties of, 564
 - clinical utility of phosphodiester oligonucleotides, 563-564
 - phosphorothioate oligonucleotides
 - efficacy of, and RNase H, 566
 - general properties, 565
 - nonspecific effects, 565-566
 - pharmacokinetics, 566-569
 - second-generation oligonucleotides, pharmacokinetics, 568
- Oncolytic virotherapy
- addition of exogenous genes, 543-545
 - adenoviral vectors for, 579-580
 - clinical trial results of dl1520 (ONYX-015), 542-543
 - designing and screening vectors, 545
 - mechanisms for achieving tumor targeting or selectivity
 - bioselection approaches, 542
 - inherently selective viruses, 538
 - tumor- or tissue-specific expression of early viral genes, 540-541
 - viral gene deletion mutants, 539-540
 - virus retargeting for tumor-selective uptake, 541-542
 - virus selection and design, 537-538
- Onconase, in malignant pleural mesothelioma, 341
- ONYX-015, 92
- for oncolytic virotherapy, clinical trial results, 542-543
- Optical coherence tomography, in lung cancer screening, 263
- Osteosclerosis, and myelofibrosis, in mouse models, pathogenesis of
- cytokines involved in, 368-369
 - GATA-1 expression in, 367-368
 - thrombopoietin overexpression in, 366-367
- Outcomes, of splenectomy for myelofibrosis with myeloid metaplasia, 406-407
- Oxaliplatin
- capecitabine plus, in colorectal cancer, 46-47, 49
 - in combination chemotherapy, for colorectal cancer, 98-99
 - in combined modality therapy, for rectal cancer, 107-108
 - drug pathway of, 116-117
 - response to, 124-125
 - trials of, 35-38, 40
- Oxandrolone, 204
- for anorexia, 201
- Oxaprozin, 187
- Oxycodone, 182, 183-184
- p14^{ARF}/mdm2/p53 pathway, in cell cycle progression in cancer, 454-455
- p15/INK4B, as in vivo marker of demethylation for myeloid neoplasms, 514
- p53 gene, 122-123
- in colorectal screening, 9
- Paclitaxel
- consolidation chemotherapy, in non-small cell lung cancer, 290
 - monotherapy, in non-small cell lung cancer, 308-309
- Paclitaxel, carboplatin chemotherapy regimen, in non-small cell lung cancer, 301-302, 306, 308
- adjuvant chemotherapy, 281
 - induction chemotherapy, 287-289
- Paclitaxel, carboplatin chemotherapy regimen, in non-small cell lung cancer, 301-302, 306, 308 (*Continued*)
- Paclitaxel, cisplatin chemotherapy regimen, in non-small cell lung cancer, 302, 309
- induction chemotherapy, 288
- Paclitaxel, gemcitabine chemotherapy regimen, in non-small cell lung cancer, 303, 309
- Pain, of cancer, *see* Cancer pain
- Palliative care
- definition of, 131
 - end points in, 167
 - mixed management models of, 147
 - surgical interventions in, 166
- Palliative chemotherapy, 147-149
- alternatives to, 152
 - in non-small cell lung cancer, 151
 - outcomes of, 150
 - in pancreatic cancer, 150
 - in prostate cancer, 151-152
 - quality of life and, 149
 - toxicity of, 149-150
- Palliative medicine
- acute inpatient, 135-136
 - acute inpatient unit of, 135
 - consultation service in, 135
 - evidence-based research in, 137
 - financial aspects of, 136
 - home care service of, 135
 - medical oncology and, 134
 - nurse case management in, 136
 - outpatient clinic service of, 135
 - patient service access points in, 136
 - physician education in, 137
 - physician in, 134-135
- Palliative radiation therapy
- external-beam, 156-158
 - for extramedullary hematopoiesis in myelofibrosis with myeloid metaplasia
 - abdominal radiation, 408-410
 - external-beam radiotherapy, 408
 - liver radiation, 408-410
 - lung radiation, 410
 - splenic radiation, 408
 - fractional schedules in, 157
 - large-field, 158
 - single-fraction, 157
- Palliative sedation, 238
- Palliative surgery, definition of, 165
- Palliative treatment, in non-small cell lung cancer, 251
- Pamidronate, 187, 189
- Pancreas, metastatic disease to, palliative radiation therapy in, 160
- Pancreatic cancer, palliative chemotherapy in, 150-152
- Panitumumab, clinical development of, 55, 56
- Paravertebral nerve block, 197
- Patient selection, for splenectomy, in myelofibrosis with myeloid metaplasia, 407
- PDGF, *see* Platelet-derived growth factor
- Pemetrexed
- in colorectal cancer, 38-39
 - in malignant pleural mesothelioma, 339-341
 - plus cisplatin, 340-341
- Peptide vaccine, trials of, 78-79
- Percutaneous catheter, 195
- Percutaneous ethanol infiltration, in metastatic colorectal cancer, 88
- Peripheral neurolysis, 197-198
- Peutz-Jegher's syndrome
- colorectal cancer risk and, 12
 - diagnostic criteria for, 18
 - genetics of, 17-18
 - screening guidelines for, 18
- Phase I trial, of chemotherapy, 152-154

- Phenytoin, 187, 189
- PhoenixCare, 147, 148
- Phosphate soda enema, 182
- Phosphodiester oligonucleotides, for oncogene inactivation, clinical utility, 563-564
- Phosphorothioate oligonucleotides, for oncogene inactivation
 efficacy of, and RNase H, 566
 general properties, 565
 nonspecific effects, 565-566
 pharmacokinetics, 566-569
- Physician-assisted suicide, v sedation, 239-240
- Pirfenidone, for myelofibrosis with myeloid metaplasia, 427
- Piroxicam, chemoprevention trial and, 26
- PKI 166, clinical development of, 55, 57
- Platinum, vindesine chemotherapy regimen, in non-small cell lung cancer, 279-280
- Platinum-based doublets, in non-small cell lung cancer, 300-302
 carboplatin, docetaxel regimen, 301-302
 carboplatin, gemcitabine regimen, 302
 carboplatin, paclitaxel regimen, 301-302, 306, 308
 cisplatin, docetaxel regimen, 301-302
 cisplatin, etoposide regimen, 309
 cisplatin, gemcitabine regimen, 300-302
 cisplatin, irinotecan regimen, 301
 cisplatin, paclitaxel regimen, 302, 309
 cisplatin, vindesine regimen, 300-301, 308
 cisplatin, vinorelbine regimen, 301-302, 308
 in relation to age, 308-310
- Pleural mesothelioma, malignant, 251, 335-345
 anti-EGFR antibody therapy, 341-343
 Avastin, 343-344
 bevacizumab, 343-344
 chemotherapy, 336-341
 computed tomography, 336-337
 EGFR-tyrosine kinase inhibitors, 342-343
 GFB-111, 343
 Gleevec, 343
 hepatocyte growth factor/scatter factor, 344
 imatinib mesylate, 343
 leflunomide, 343
 magnetic resonance imaging, 337
 mammalian target of rapamycin, 344
 molecular targeted therapy, 341-345
 onconase, 341
 pemetrexed, cisplatin regimen, 340-341
 treatment, 339-341
 platelet-derived growth factor inhibitors, 343
 positron emission tomography, 337-338
 factors, 335-336
 proteasome/ubiquitin pathway, 344-345
 PTK 787, 343
 ranpirase, 341
 response to chemotherapy, 336-338
 SU101, 343
 SU5416, 343
 SU11274, 343
 thalidomide, 343-344
 vascular endothelial growth factor inhibitors, 343-344
- Polyethylene glycol, 182
- Polymorphism, 11307K APC, 19
 colorectal cancer risk and, 12
- Poppy seed oil, iodinated, 170
- Portal hypertension, in myelofibrosis with myeloid metaplasia, surgical palliation of, 408
- Positron emission tomography
 in lung cancer screening, 262
 in malignant pleural mesothelioma, 337-338
 staging of mediastinal lymph node metastasis, 271, 275-276
- Post-operative complications
 of mediastinoscopy, 273
 of mediastinotomy, 273
- Poxviral vaccines, for cancer immunotherapy, 549
 costimulation into, 551-552
 tumor-associated antigens and, 550
 clinical trials, 550-553
- pRB/p16^{INK4}/cyclin D1 pathway, in cell cycle progression in cancer, 452-454
- Prednisone, 187
- Prefibrotic stage, of myelofibrosis with myeloid metaplasia, 381-382
- Prevention of lung cancer, chemoprevention, 265
- Primary effusion lymphoma, epigenetic immunotherapy for, 505
- Principle of double effect, 240
- Prinomastat, in non-small cell lung cancer, 320
- Prognosis, and histopathology, of myelofibrosis with myeloid metaplasia, 389-391
- Prognostic factors
 of bronchioloalveolar carcinoma, 330
 of malignant pleural mesothelioma, 335-336
 and staging systems, of myelofibrosis with myeloid metaplasia, 399-401
- Project Safe-Conduct, 147, 148
- Proliferation, and apoptosis, in myelofibrosis with myeloid metaplasia, 383-385
- Prophylactic cranial irradiation, in central nervous system metastasis, 293-296
- Propofol, for extraordinary sedation, 243
- Prostate cancer
 palliative chemotherapy in, 150-152
 palliative radiation therapy in, 161
 poxviral vaccines for, 553
- Prostate-specific antigen (PSA), and poxviral vaccines
 in cancer immunotherapy, 550
 clinical trials of, 552-553
- Proteasome/ubiquitin pathway, in malignant pleural mesothelioma, 344-345
- Protein kinase c inhibitors, in non-small cell lung cancer, 320
- Protein vaccine, trials of, 78-79
- Proteomic approach, in lung cancer screening, 264-265
- PSA, see Prostate-specific antigen
- Psychoeducational intervention, 215
- Psychosocial oncology, definition of, 212
- PTK 787, in malignant pleural mesothelioma, 343
- Qigong, 226-227
- Quality of life, 145-146
 palliative chemotherapy and, 149
- Radiation
 capecitabine plus, 106
 in rectal cancer, 49-50
 ultraviolet, exposure to, relationship with DNA methylation in cutaneous malignancies, 484
- Radiation therapy, see Radiotherapy
- Radiofrequency ablation, of colorectal cancer hepatic metastases, 86-87
- Radiofrequency neurolysis, 196
- Radiofrequency thermogangliolysis, 197
- Radionuclide, systemic, 158
- Radiosurgery, 159
- Radiotherapy
 for extramedullary hematopoiesis in myelofibrosis with myeloid metaplasia
 abdominal radiation, 408-410
 external-beam radiotherapy, 408
 liver radiation, 408-410
 lung radiation, 410
 splenic radiation, 408
- in non-small cell lung cancer
 continuous hyperfractionated accelerated radiation therapy v chemotherapy, 287
 hyperfractionated accelerated radiation therapy plus induction chemotherapy, 287-288
 hyperfractionated radiation therapy plus chemotherapy, 287

- Radiotherapy (*Continued*)
 plus adjuvant chemotherapy, 280
 plus induction chemotherapy, 286-291
 and surgery plus induction chemotherapy, 284-285
 v hyperfractionated radiation, 287-288, 290-291
 palliative, *see* Palliative radiation therapy
 whole-brain, 159
- Ranpirnase, in malignant pleural mesothelioma, 341
- Rattle, treatment of, 207
- Rectal cancer
 capecitabine plus radiation in, 49-50
 chemoradiation in, 49-50
 combined modality therapy in, 103-104
 palliative radiation therapy in, 160
 pre- v postoperative adjuvant therapy in, 105-106
 sphincter preservation in, 104
- Refractory non-small cell lung cancer, 306-307
- Replication-selective virotherapy, 92
- Respiratory symptoms
 endobronchial radiation for, 159-160
 external-beam radiation therapy for, 159
- Retinoids, in non-small cell lung cancer, 320
- Ribozymes, for multidrug resistant cancer gene therapy, 585, 587
- RNA interference
 in cancer, 522
 in multidrug resistant cancer gene therapy, 586
- RNAse H, and mechanism of antisense efficacy for oncogene inactivation, 566
- RNA-transfected dendritic cells, for cancer immunotherapy, clinical trials of, 557-559
- Rofecoxib, in combination therapy, for colorectal cancer, 73
- Royal Marsden Hospital, palliative medicine in, 137
- Saltz regimen, 36
- Samarium-153, 187, 189
- SCH 58500, 91
- Sclerosant injection, 175
- Scopolamine, 207
- Screening
 lung cancer, 259-266
 biomarkers, 265
 bronchoscopy, 259, 262
 confocal microscopy, 263
 epigenetic alterations, 264
 fluorescence bronchoscopy, 259, 262
 gamma camera screening, 263
 genetic alterations, 263-264
 genetic predisposition, 261
 genomic instability, 264
 high-resolution computed tomography, 259, 262
 high-risk population, 260-261
 low-dose spiral computed tomography, 261-262
 magnetic resonance imaging, 263
 matrix-assisted laser desorption ionization-mass spectroscopy, 265
 molecular imaging, 263
 molecular profiling, 264
 near-infrared Raman spectroscopy, 263
 optical coherence tomography, 263
 positron emission tomography, 262
 proteomic approach, 264-265
 sputum cytology, 260-261
 non-small cell lung cancer, 251, 253-257
 autofluorescence bronchoscopy, 254
 chest roentgenogram, 254-257
 computed tomography, 254
 low-dose spiral computed tomography, 256-257, 261
 sputum cytology, 254-257
- Screening recommendations, for colorectal cancer, 5, 6
- Sedation
 dehydration following, 241
- Sedation (*Continued*)
 drugs for, 242-244
 extraordinary, 243-244
 infrequent, 242-243
 for intractable distress in dying patient, 238
 palliative, 238
 patient monitoring in, 244
 patient selection for, 241-242
 routine, 242
 starvation following, 241
 terminal, 237-238
- Selenium
 chemoprevention trial of, 26
 in colorectal cancer, 30
- Self-expanding metal stent, 174-175
 in esophageal obstruction, 175
- Semaxanib, in non-small cell lung cancer, 321
- Sentinel lymph node mapping, staging of mediastinal lymph node metastasis, 274-275
- Signal transduction inhibitors, for myelofibrosis with myeloid metaplasia, 426-427
- Signaling, and transcription factors, in stem cell dysregulation, in myelofibrosis with myeloid metaplasia, 375-376
- Simultaneous Care Model, 147, 148
- SirSphere, 170
- Solid tumors
 clinical development of decitabine for, 469
 epigenetic immunotherapy for
 cancer testis antigens and, 474
 DNA hypomethylating agents for, 475-477
 HLA antigens and, 475-476
- Spinal cord compression, 159
- Spinal/paraspinal extramedullary hematopoiesis, in myelofibrosis with myeloid metaplasia, 410
- Spirituality, clinical impact of, 233-235
- Splenectomy, for myelofibrosis with myeloid metaplasia, 405-407
 long-term complications of, 407
 outcomes of, 406-407
 patient selection for, 407
- Splenic radiation, for extramedullary hematopoiesis, in myelofibrosis with myeloid metaplasia, 408
- Splenomegaly, palliative radiation therapy in, 161
- Sputum cytology
 in lung cancer screening, 260-261
 in non-small cell lung cancer screening, 254-257
- Squamous cell carcinoma, aberrant DNA methylation in, 480-481
 relationship with exposure to ultraviolet radiation, 484
- Staging
 mediastinal lymph node metastasis, 269-276
 computed tomography, 270-271, 273
 dissection, 274-275
 endobronchial ultrasound, 272, 275
 endo-esophageal ultrasound fine-needle aspiration, 272
 lymphadenectomy, 272
 magnetic resonance imaging, 271
 mediastinoscopy, 272-275
 mediastinotomy, 272-274
 positron emission tomography, 271, 275-276
 sentinel lymph node mapping, 274-275
 transbronchial needle aspiration, 271-272
 video-assisted thoracoscopic surgery, 273-274
 non-small cell lung cancer, 251
- Staging systems, and prognostic factors, of myelofibrosis with myeloid metaplasia, 399-401
- Starvation, following sedation, 241
- Stem cell dysregulation, in myelofibrosis with myeloid metaplasia, 373-377
 hematopoietic and fibrogenic growth factors and their receptors, 374-375
 hematopoietic progenitors and stromal interactions, 375
 signaling and transcription factors in, 375-376

- Stool-based DNA testing, 8-9
- Stromal interactions, and hematopoietic progenitors, in stem cell dysregulation in myelofibrosis with myeloid metaplasia, 375
- Strontium 89, 158, 187, 189
- SU101, in malignant pleural mesothelioma, 343
- SU5416, in malignant pleural mesothelioma, 343
- SU6668, in non-small cell lung cancer, 321-322
- SU11274, in malignant pleural mesothelioma, 344
- Suicide gene therapy, in cancer, adenoviral vectors for, 578
- Sulindac efloirithine, chemoprevention trial of, 26
- Sumarium 153, 158
- Superior vena cava syndrome, palliative radiation therapy for, 160
- Support group, 215
- Surgery
 for myelofibrosis with myeloid metaplasia, 403-408
 splenectomy, 405-407
 in non-small cell lung cancer
 plus adjuvant chemotherapy, 279-281
 and radiotherapy plus induction chemotherapy, 284-285
 palliative, definition of, 165
- Surveillance recommendations, for colorectal cancer, 5
- Survival, and natural history, in myelofibrosis with myeloid metaplasia, 398
- Targeted therapy, in non-small cell lung cancer, 315-325
 affinitak, 320
 angiogenesis inhibitors, 320-323
 anti-EGFR monoclonal antibody therapy, 317-318
 anti-VEGFR monoclonal antibody therapy, 321
 bevacizumab, 321
 bexarotene, 320
 celoxib, 323
 cetuximab, 317-318
 cyclooxygenase-2 inhibitors, 323
 EGFR inhibition, 316-317
 erlotinib, 318-319
 farnesyl transferase inhibitors, 319
 gefitinib, 318-319
 HER2 inhibition, 319
 lonafarnib, 319
 matrix metalloproteinase inhibitors, 320
 neovastat, 320
 prinomastat, 320
 protein kinase c inhibitors, 320
 retinoids, 320
 semaxanib, 321
 SU6668, 321-322
 tipifarnib, 319
 trastuzumab, 319
 ZD6126, 322
 ZD6474, 322
- TBNA, *see* Transbronchial needle aspiration
- Telomerase activity, reduced by decitabine in epigenetic cancer therapy, 466
- Terminal sedation, 237-238
- Tezacitabine, in colorectal cancer, 39-40
- Thalidomide, 204
 in colorectal cancer, 65, 66
 in malignant pleural mesothelioma, 343-344
- Thermal ablation, definition of, 172
- Thiopental, for extraordinary sedation, 243
- Thoracoscopic surgery, video-assisted, staging of mediastinal lymph metastasis, 273-274
- Thrombopoietin overexpression, role in pathogenesis of myelofibrosis and osteosclerosis in mouse models, 366-367
- Thymidine phosphorylase, 122
- Thymidine synthase, 113-114
- Thymidylate synthase, 120-122
- Tipifarnib, in non-small cell lung cancer, 319
- TNM classification, of colorectal cancer, 96
- Tomography, optical coherence, *see* Optical coherence tomography
- Total sedation, 238
- Toxin conjugates, *see* Immunotoxin(s)
- TPO, *see* Thrombopoietin
- Traditional Chinese medicine, 225-226
- Tramadol, 183
- Transbronchial needle aspiration, staging of mediastinal lymph node metastasis in lung cancer, 271-272
- Transcription factors, and signaling, in stem cell dysregulation, in myelofibrosis with myeloid metaplasia, 375-376
- Transcutaneous electrical nerve stimulation, 198
- Trastuzumab, in non-small cell lung cancer, 319
- Tricyclic antidepressant, as coanalgesic, 188-189
- Trigeminal balloon compression, 197
- Triple-forming oligonucleotides, for multidrug resistant cancer gene therapy, 585-586
- Tumor suppressor genes
 hypermethylation in cancer, 522-523
 transfer of, 91
- Tumor-associated antigens
 and epigenetic immunotherapy for solid tumors
 cancer testis antigens, 474
 HLA antigens, 475-476
 genetically modified dendritic cell vaccines with, 556
 clinical trials, 557-559
 preclinical studies, 557
 problems with clinical development, 559-560
 rationale, 557
 induction by decitabine for epigenetic cancer therapy, 466
 and poxviral vaccines, 550
 clinical trials, 550-553
- Tumor-specific targeted therapy, in non-small cell lung cancer, 251
- Two hit hypothesis, 13
- Tyrosine kinase phosphorylation, 53
- UFT, *see* Uracil tegafur
- Ultrasound, endobronchial, staging of mediastinal lymph node metastasis, 272
- Ultraviolet radiation, exposure to, relationship with DNA methylation in cutaneous malignancies, 484
- Uracil tegafur adjuvant chemotherapy, in lung adenocarcinoma, 281
- Ursodeoxycholic acid, 29
 chemoprevention trial of, 26
- Vaccine
 dendritic cell, *see* Dendritic cell vaccines
 goals of, 77-78
 poxviral, *see* Poxviral vaccines
 types of, 78
 varying formats of, 77
- Vaccine therapy, in non-small cell lung cancer, 282
- Vaccinia, 80
- Vascular endothelial growth factor
 anti-, inhibitors of, 62-63
 biology of, in tumor angiogenesis, 62
- Vascular endothelial growth factor inhibitors, in malignant pleural mesothelioma, 343-344
- Vascular obstruction, 170-171
- Vascular therapy, 169-170
- Vatalanib, in colorectal cancer, 65, 66
- VATS, *see* Video-assisted thoracoscopic surgery
- Vectors, adenoviral, *see* Adenoviral vectors
- VEGF, *see* Vascular endothelial growth factor
- Video-assisted thoracoscopic surgery, staging of mediastinal lymph metastasis, 273-274
- Vinblastine, cisplatin induction chemotherapy regimen, in non-small cell lung cancer, 286

- Vinblastine, mitomycin, cisplatin chemotherapy regimen, in non-small cell lung cancer, 306
 induction chemotherapy, 287
- Vindesine, cisplatin chemotherapy regimen, in non-small cell lung cancer, 300-301, 308
 induction chemotherapy, 284-285
- Vindesine, mitomycin, cisplatin adjuvant chemotherapy regimen, in non-small cell lung cancer, 280-281
- Vindesine, platinum chemotherapy regimen, in non-small cell lung cancer, 279-280
- Vinorelbine, cisplatin chemotherapy regimen, in non-small cell lung cancer, 300-302, 308
 adjuvant chemotherapy, 281
 induction chemotherapy, 288
- Vinorelbine, gemcitabine, cisplatin chemotherapy regimen, in non-small cell lung cancer, 303-305
- Vinorelbine, gemcitabine chemotherapy regimen, in non-small cell lung cancer, 303, 308-309
- Vinorelbine, ifosfamide chemotherapy regimen, in non-small cell lung cancer, 303-304
- Vinorelbine monotherapy, in non-small cell lung cancer, 300, 308-309
- Virally encoded vaccine, trial of, 80-81
- Virotherapy, for cancer, see Oncolytic virotherapy
- Virtual colonoscopy, 8
- Viruses, for cancer therapy, see Oncolytic virotherapy
- Vitamins, chemoprevention trial and, 26
- Wellness Community, 216
- Whole cell vaccine, 77
 trials of, 78
- Wnt signaling pathway, 14
- World Health Organization, cancer management model of, 135
- XELIRI regimen, in colorectal cancer, 48-49
- Xeloda adjuvant chemotherapy trial, 45
- XELOX regimen, in colorectal cancer, 46-48
- Yoga, 228
- Young Survival Coalition, 216
- ZD6126, in non-small cell lung cancer, 322
- ZD6474, in non-small cell lung cancer, 322
- Zolendronate, 187, 189